Many companies have announced that they are experiencing disruptions to their clinical trials for non-Covid-19 indications due to the strict lockdown measures that many countries have implemented. Many have delayed the initiation of planned trials or withdrawn the trials completely, and others have suspended enrolment in their ongoing trials or terminated the trials altogether.
The COVID-19 Dashboard on GlobalData’s Pharma Intelligence Center dynamically tracks both these disrupted trials and trials that have resumed activity. It reveals that more than 130 trials are currently resuming, and more trials are being added to this category daily.
Go deeper with GlobalData
To read more, please click here.
